Should Methotrexate Have Any Place in the Treatment of Psoriatic Arthritis?

Weiyu Ye; Laura C Coates

doi:10.1016/j.rdc.2019.04.007

Should Methotrexate Have Any Place in the Treatment of Psoriatic Arthritis?

Rheum Dis Clin North Am. 2019 Aug;45(3):325-339. doi: 10.1016/j.rdc.2019.04.007. Epub 2019 May 30.

Authors

Weiyu Ye¹, Laura C Coates²

Affiliations

¹ Oxford University Clinical Academic Graduate School, University of Oxford, John Radcliffe Hospital (Main Hospital), Room 3A31, The Cairns Library IT Corridor, Level 3, Oxford OX3 9DU, UK.
² Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, Windmill Road, Oxford OX3 7LD, UK. Electronic address: laura.coates@ndorms.ox.ac.uk.

PMID: 31277747
DOI: 10.1016/j.rdc.2019.04.007

Abstract

Methotrexate (MTX) is widely used in the treatment of psoriatic arthritis (PsA), despite the evidence base for this being limited. This narrative review summarizes the evidence to date of using MTX within different domains of psoriatic disease, including peripheral arthritis, axial disease, dactylitis, enthesitis, psoriasis, and nail disease. We also explore the role of MTX in combination therapy with tumor necrosis factor inhibitors, in addition to its safety and tolerability, to answer the question: should methotrexate have any place in the treatment of psoriatic arthritis?

Keywords: Efficacy; Methotrexate; Psoriasis; Psoriatic arthritis; Treatment.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antirheumatic Agents / pharmacology
Arthritis, Psoriatic / drug therapy*
Humans
Methotrexate / pharmacology*
Treatment Outcome

Substances

Antirheumatic Agents
Methotrexate